Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Volatility & Risk
Alpha Cognition has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Alpha Cognition and Cognition Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 1 | 0 | 3.00 |
| Cognition Therapeutics | 0 | 1 | 5 | 1 | 3.00 |
Valuation & Earnings
This table compares Alpha Cognition and Cognition Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | N/A | N/A | -$13.77 million | ($2.56) | -2.16 |
| Cognition Therapeutics | N/A | N/A | -$25.79 million | ($0.87) | -0.51 |
Alpha Cognition is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Alpha Cognition and Cognition Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | N/A | N/A | -344.17% |
| Cognition Therapeutics | N/A | -150.93% | -100.82% |
Insider and Institutional Ownership
43.3% of Cognition Therapeutics shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 20.8% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Cognition Therapeutics beats Alpha Cognition on 7 of the 11 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
